HealthCare Royalty Partners
http://www.healthcareroyalty.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From HealthCare Royalty Partners
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Abbott Among Firms Gaining Formula Import Approvals As Flood Closes Its Michigan Plant
Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.
Rhythm Leans On Imcivree Rare Disease Commercialization For New Indication
The company got FDA approval for the drug in Bardet-Biedl syndrome, on top of the existing approval from November 2020 in obesity due to POMC, PCSK1 and LEPR deficiency.
Company Information
- Industry
- Miscellaneous